Form 4: Moderna CFO James Mock Reports Stock Transactions
SEC Form 4
James Mock, Moderna's Chief Financial Officer, reported the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.
Summary
- On February 28, 2025, James Mock, the Chief Financial Officer of Moderna, engaged in transactions involving Moderna's common stock.
- These transactions included the conversion of 329 restricted stock units into common stock and the withholding of 160 shares to cover tax obligations at a price of $31.09.
- Following these transactions, Mock directly owns 14,874 shares of Moderna common stock.
- Mock also acquired 63,478 stock options with an exercise price of $30.96, vesting quarterly starting March 1, 2026, and expiring on March 1, 2035.
- Additionally, Mock acquired 39,606 restricted stock units, vesting quarterly starting March 1, 2026.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Moderna. It provides transparency regarding the transactions of company insiders.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are standard components of executive compensation packages in the biotechnology industry.
- Vesting schedules, such as the quarterly vesting described, are typical for these types of equity awards.
- Companies like Pfizer, BioNTech, and Novavax also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CFO's holdings.
- Employees may be indirectly affected by the vesting of stock options and restricted stock units, as these are part of the overall compensation structure.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | 25% of certain restricted stock units vested |
| 02/28/2025 | Transactions involving common stock and restricted stock units occurred. |
| 03/01/2025 | Grant date of stock options and restricted stock units. |
| 03/01/2026 | 25% of stock options and restricted stock units will vest, with the remainder vesting quarterly thereafter. |
| 03/01/2035 | Expiration date of the stock options. |
| 03/03/2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.